RxDoctor Payments Data

Katelyn Coleman

Family · Festus, MONPI 1619590205

Payments from drug & device makers

$4,682in general payments, 2019–2025

Across 261 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$621
  • Novartis$505
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$496
  • Amgen$373
  • Esperion Therapeutics, Inc.$338
  • Johnson & Johnson$310
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,682 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$18,971
Medicare patients
168
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$128,022
EntrestoSacubitril/Valsartan44$58,401
JardianceEmpagliflozin42$46,077
BrilintaTicagrelor25$21,345
XareltoRivaroxaban11$16,228
Repatha SureclickEvolocumab17$8,996
Metoprolol Succinate143$1,230
Bumetanide13$1,154
Prasugrel Hcl11$990
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$908
Amiodarone Hcl51$860
Atorvastatin Calcium98$824
Isosorbide Mononitrate ErIsosorbide Mononitrate76$650
Carvedilol87$634
Furosemide126$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$128,022127 claims
NovartisEntresto$505$58,40144 claims
Boehringer IngelheimJardiance$621$46,07742 claims
AstraZenecaBrilinta$215$21,34525 claims
Johnson & JohnsonXarelto$310$16,22811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →